Investigation Report on China's Omalizumab Market 2021-2025
|出版商||China Research and Intelligence||商品編碼||1009409|
|出版日期||內容資訊||英文 50 Pages
|中國的Omalizumab市場分析 (2021年∼2025年) Investigation Report on China's Omalizumab Market 2021-2025|
|出版日期: 2021年06月04日||內容資訊: 英文 50 Pages||
Omalizumab，是現在中國上市的唯一氣喘治療的單株抗體。2021前半年，Novartis Europharm是中國國內唯一的廠商。成中國的Omalizumab的銷售量有擴大趨勢，2018年∼2020年的年複合成長率成為163.2％，2020年的銷售額達4161萬人民幣 (與前一年同期比較增加281.5％) 。由於中國氣喘的死亡率在世界最高，市場今後也將繼續擴大趨勢。
Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE). At the end of 2017, the FDA approved the registration of Novartis Europharm ' Omalizumab, which will enter the field of anti-COPD and moderate to severe persistent allergic asthma. Since then, Omalizumab has been officially launched in China. Omalizumab is the only monoclonal antibody currently on the market in China for the treatment of asthma. By the first half of 2021, Novartis Europharm is the only manufacturer in the Chinese Omalizumab market.
According to CRI's market research, Omalizumab sales have increased year by year from 2018 to 2020. At the beginning of 2020, Omalizumab was included in China's medical insurance as a treatment for respiratory diseases. During the period of the COVID-19 epidemic, the sales of Omalizumab has increased. Therefore, its sales value reached CNY41.61 million in China in 2020, with an annual growth rate of 281.5%. The CAGR of Omalizumab's sales value in the Chinese market from 2018 to 2020 is 163.2%.
CRI predicts that with the increase in the number of indications, the sales of Omalizumab in China will continue to grow from 2021 to 2025. China is one of the countries with the highest mortality rate of asthma in the world. In 2020, there were about 30 million asthma patients in China, which was 1.5 times higher than the number of patients in 2017 (20 million). Therefore, it can be speculated that the number of indications of Omalizumab in China will continue to grow and sales will increase accordingly. Omalizumab is clinically more accurate and more effective than inhaled corticosteroids and long-acting inhaled B2-adrenergic receptor agonists, especially for patients with moderate to severe asthma. Based on these therapeutic advantages, the market share of Omalizumab will increase in the future. In addition, Omalizumab has only been approved for one indication in China, and 4 indications have been approved globally. Therefore, the number of approved indications for Omalizumab in China still has potential for growth. It can be predicted that its sales will continue to grow with the expansion of the market and the increase of the number of indications in the future.